| Biomarker ID | 930 |
| PMID | 22615945 |
| Year | 2012 |
| Biomarker | Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Cell Lines |
| Regulation | Differentially Expressed in PCA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | BPH-1, LNCaP Vs C4-2 |
| Type of Biomarker | Diagnostic |
| Cohort | 3 Prostate cancer Cell lines: BPH-1, LNCaP and C4-2 were taken into consideration for this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | two-dimensional gel electrophoresis (2-DE) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | TPI1, SPON2, THBS1, PGAM1, NPM1 |